Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 12/20 | 0.67 |
| ▸ | MMP2 | P08253 | 11/20 | 0.67 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | HPN | P05981 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 3/20 | 0.45 |
| ▸ | MMP14 | P50281 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77677 | 1.00 | MMP9 (0.67) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| Hydrochloric Acid SCHEMBL1499337 | 0.99 | MMP9 (0.65) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| Hydrochloric Acid SCHEMBL14059214 | 0.99 | MMP9 (0.65) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL457772 | 0.93 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL10585071 | 0.93 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL8001084 | 0.93 | MMP9 (0.76) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL8322406 | 0.92 | MMP9 (0.71) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| Hydrochloric Acid SCHEMBL9087107 | 0.92 | MMP9 (0.74) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL232590 | 0.91 | MMP9 (0.70) | MMP9MMP2ITGB3ITGA2BTDP1 | |
| SCHEMBL796113 | 0.91 | MMP9 (0.70) | MMP9MMP2ITGB3ITGA2BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171691-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE | 2008-07-17 | — | — | US | claimed |
| US-20050137121-A1 | Inhibiting or abolishing the protein cleaving action of plasmin, and inhibiting or abolishing the protein cleaving action of a murine metalloprotease. | LUND LEIF R (DK) | 2005-06-23 | — | — | US | claimed |
| EP-0942746-B1 | INHIBITION OF INVASIVE REMODELLING | FONDEN TIL FREMME AF EKSPERIME (DK) | 2005-03-16 | — | — | EP | claimed |
| US-20020099004-A1 | Inhibition of invasive remodelling | LUND LEIF ROGE (DK) | 2002-07-25 | — | — | US | claimed |
| US-6180402-B1 | REDUCING SIDE EFFECTS OR ENHANCING SELECTIVITY OF THERAPY BY CONTACTING LIVING CELLS WITH PHOTOSENSITIZING AGENT AND AT LEAST ONE CYSTEINE OR SERINE PROTEASE INHIBITOR | QLT INC. (CA) | 2001-01-30 | — | — | US | claimed |
| US-6121421-A | SIMPLE, EFFICIENT TWO STEP EXTRACTION PROCESS; MIXING CRUDE PREPARATION WITH BUFFER IN WHICH BETA-CASEIN IS INSOLUBLE, PELLETING BETA-CASEIN BY CENTRIFUGING, SUSPENDING PELLET IN BUFFER AND SOLUBILIZER, CENTRIFUGING, SUPERNATANT HAS CASEIN | ABBOTT LABORATORIES (US) | 2000-09-19 | — | — | US | claimed |
| WO-1998022098-A2 | CPP32 INHIBITORS FOR REGULATING APOPTOSIS | QLT PHOTOTHERAPEUTICS, INC. (CA) | 1998-05-28 | — | — | WO | claimed |
| US-4677069-A | Clam derived proteinases | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-06-30 | — | — | US | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4000905-B1 | PUNCTURE SEALANT | SUMITOMO RUBBER IND (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | MODEL MEDICINES INC (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2024103215-A1 | PHARMACEUTICAL COMBINATION FOR TREATING FATTY LIVER DISEASE AND USE THEREOF | 泽生生技股份有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-20240082228-A1 | SARS-COV-2 THERAPEUTICS | MODEL MEDICINES INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-1994012640-A1 | RECOMBINANT NUCLEIC ACID, POLYPEPTIDE MATERIAL CODED THEREBY AND TRANSMISSION BLOCKING VACCINE BASED THEREON FOR CONTROLLING THE MALARIA PARASITE $i(PLASMODIUM FALCIPARUM ) | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 1994-06-09 | — | — | WO | disclosed |
| US-5310880-A | Chromatography, alkali halide, acid solution | THE GENERAL HOSPITAL CORPORATION (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0554064-A1 | Vaccine against schistosomiasis | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992018145-A1 | PURIFICATION OF MÜLLERIAN INHIBITING SUBSTANCE | THE GENERAL HOSPITAL CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0323802-A2 | Monoclonal antibodies against, and cell surface antigen of, lung carcinoma | SANDOZ AG (CH) | 1989-07-12 | — | — | EP | disclosed |
| US-4677069-A | Clam derived proteinases | CORNELL RESEARCH FOUNDATION, INC. (US) | 1987-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | MMP9 2494/4885MMP2 4687/4885ITGB3 2892/4885 |
| US-20250025454-A1 | USE OF PIPENDOXIFENE TO TREAT SARS-COV-2 INFECTION | EIF2AK2, ACE2, SARS1 | MMP9 2057/4885MMP2 3595/4885ITGB3 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.